Evidence map›Paper›PMID 40021267›Full record

ArticleJACC. Advances2025

Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy.

Ting-Wei Kao, Yi-Hsin Hung, An-Li Yu, Mei-Feng Cheng, Mao-Yuan Su, Chi-Chao Chao, Cheng-Hsuan Tsai, Yen-Hung Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Therapy of amyloidosis: stabilizers and silencers.European heart journal supplements : journal of the European Society of Cardiology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ting-Wei KaoDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yi-Hsin HungDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Cardiovascular Centre, National Taiwan University Hospital, Taipei, Taiwan.
An-Li YuDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Cardiovascular Centre, National Taiwan University Hospital, Taipei, Taiwan.
Mei-Feng ChengDepartment of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan; Institute of Environmental and Occupational Health Sciences, National Taiwan University, Taipei, Taiwan.
Mao-Yuan SuDepartment of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu, Taiwan.
Chi-Chao ChaoDepartment of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
Cheng-Hsuan TsaiDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University College of Medicine, Graduate Institute of Clinical Medicine, Taipei, Taiwan. Electronic address: chenghsuan.richard.tsai@gmail.com.
Yen-Hung LinDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Cardiovascular Centre, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: austinr34@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) has recently gained recognition as a rare and fatal disease. Tafamidis, a first-in-class transthyretin stabilizer, has emerged as a promising agent for attenuating disease progression. Nevertheless, how tafamidis alters clinical and imaging parameters remains unclear.

objectivesThis systemic review and meta-analysis aimed to investigate how tafamidis remodels the myocardium and influences the disease trajectory of ATTR-CM.

methodsPubMed, EMBASE, and the Cochrane Library were searched for literature from inception to February 2024 which reported either the effects of tafamidis treatment or natural course of ATTR-CM. Outcomes of interests were all clinical and imaging parameters available from at least 2 independent studies.

resultsWe identified 30 studies comprising 2,973 participants with ATTR-CM. Pooling all studies with outcomes of both tafamidis and placebo, tafamidis significantly reduced all-cause mortality (OR: 0.19; 95% CI: 0.07 to 0.56) and cardiovascular death (OR: 0.08; 95% CI: 0.02-0.30). Tafamidis also ameliorated the deterioration of 6-minute walk distance (standardized mean difference [SMD] 0.04 vs. -0.29, P = 0.002) and serum N-terminal pro-B-type natriuretic peptide level (SMD: -0.03 vs 0.41, P < 0.001). Regarding imaging parameters, better global longitudinal strain on echocardiography (SMD: 0.06 vs 0.50, P = 0.003), heart to contralateral ratio (SMD: -0.23 vs. -1.17, P = 0.037) on technetium-99m pyrophosphate scintigraphy, extracellular volume (P = 0.003), left (P < 0.001) and right (P = 0.001) ventricular ejection fraction, and right atrium area (P = 0.033) on cardiac magnetic resonance imaging were observed after tafamidis treatment.

conclusionsTafamidis improves clinical outcomes and limits the progression of cardiac remodeling in ATTR-CM.

Indexed as

amyloidosismeta-analysistafamidistissue characterizationtransthyretin cardiomyopathy

Identifiers

PMID40021267
PMCPMC11905165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.